Brind.

Morgan Stanley assigned an Equal-Weight rating to Genmab on July 3, 2025.

1 report, 0 independent Updated Jul 3

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

SpeculativeNo independent reporting found

Who's involved

What this event is mainly about

Genmab Morgan Stanley

Keep exploring

The entities involved

Genmab
Danish healthcare company
- Genmab and Incyte have entered into a collaboration to evaluate new cancer treatments.Sat 11:54
- Genmab's results are advancing its ambition to lead in the field of gynecologic oncology.Fri 18:09
Morgan Stanley
U.S. investment bank
- Bank of America and Morgan Stanley are restricting third-party AI agents amid cybersecurity scares and a declared bank run threat.Sun 13:24
- Corning saw rating changes and price target adjustments from Morgan Stanley and Truist Financial, alongside increased shareholding by the Czech National Bank.Sun 11:07

Coverage

Newest first; wire copies grouped

Jul 3Unknown outlet